ArticlePeerJ2013
A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ.
Article in PeerJ, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 66 citations in OpenAlex.
- Skin on Drugs: Psychotropic Compounds in Cutaneous Biology.International journal of molecular sciences · 2026Review
- Integrated lipidomic and transcriptomic profiling of imiquimod-induced psoriasiform dermatitis.Frontiers in cell and developmental biology · 2026Article
- Topical β-Caryophyllene for Dermatologic Disorders: Mechanisms, Human Evidence, and Clinical Translation.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The effect of cannabinoids on wound healing: A review.Health science reports · 2024Review
- The Perspective of Cannabidiol in Psoriasis Therapy.Psoriasis (Auckland, N.Z.) · 2024Review
- Cannabinoids and Their Receptors in Skin Diseases.International journal of molecular sciences · 2023Review
- Specific Activation of CB2R Ameliorates Psoriasis-Like Skin Lesions by Inhibiting Inflammation and Oxidative Stress.Inflammation · 2023Article
- The Skin and Natural Cannabinoids-Topical and Transdermal Applications.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.Cells · 2022Review
- Phytocannabinoids Stimulate Rejuvenation and Prevent Cellular Senescence in Human Dermal Fibroblasts.Cells · 2022Article
- Natural Hemp-Ginger Extract and Its Biological and Therapeutic Efficacy.Molecules (Basel, Switzerland) · 2022Article
- The Effects of Nutrient Signaling Regulators in Combination with Phytocannabinoids on the Senescence-Associated Phenotype in Human Dermal Fibroblasts.International journal of molecular sciences · 2022Article
- The cannabinoid receptors system in horses: Tissue distribution and cellular identification in skin.Journal of veterinary internal medicine · 2022Article
- Cannabinoids in rheumatology: Friend, foe or a bystander?Musculoskeletal care · 2022Review
- Topical cannabidiol (CBD) in skin pathology - A comprehensive review and prospects for new therapeutic opportunities.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2022Review
- Cannabidiol (CBD) in Cancer Management.Cancers · 2022Review
- Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.International journal of molecular sciences · 2021Review
- Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabinoid receptors (CB) are expressed throughout human skin epithelium. CB1 activation inhibits human hair growth and decreases proliferation of epidermal keratinocytes. Since psoriasis is a chronic hyperproliferative, inflammatory skin disease, it is conceivable that the therapeutic modulation of CB signaling, which can inhibit both proliferation and inflammation, could win a place in future psoriasis management. Given that psoriasis is characterized by up-regulation of keratins K6 and K16, we have investigated whether CB1 stimulation modulates their expression in human epidermis. Treatment of organ-cultured human skin with the CB1-specific agonist, arachidonoyl-chloro-ethanolamide (ACEA), decreased K6 and K16 staining intensity in situ. At the gene and protein levels, ACEA also decreased K6 expression of cultured HaCaT keratinocytes, which show some similarities to psoriatic keratinocytes. These effects were partly antagonized by the CB1-specific antagonist, AM251. While CB1-mediated signaling also significantly inhibited human epidermal keratinocyte proliferation in situ, as shown by K6/Ki-67-double immunofluorescence, the inhibitory effect of ACEA on K6 expression in situ was independent of its anti-proliferative effect. Given recent appreciation of the role of K6 as a functionally important protein that regulates epithelial wound healing in mice, it is conceivable that the novel CB1-mediated regulation of keratin 6/16 revealed here also is relevant to wound healing. Taken together, our results suggest that cannabinoids and their receptors constitute a novel, clinically relevant control element of human K6 and K16 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.